URI
65
5
BA
54
5
NKE
36
6
PPL
54
-5
URBN
56
14
PGR
65
2
CMG
72
5
FITB
63
3
HCA
44
-2
PNC
64
4
MA
64
7
LMT
34
2
UNP
52
7
HST
49
-9
SE
61
-4
FSLR
54
7
BAC
53
3
BF.B
33
2
IR
66
3
NEE
50
-5
URI
65
5
BA
54
5
NKE
36
6
PPL
54
-5
URBN
56
14
PGR
65
2
CMG
72
5
FITB
63
3
HCA
44
-2
PNC
64
4
MA
64
7
LMT
34
2
UNP
52
7
HST
49
-9
SE
61
-4
FSLR
54
7
BAC
53
3
BF.B
33
2
IR
66
3
NEE
50
-5
Financhill
Back

Akero Therapeutics Quote, Financials, Valuation and Earnings

Invest. Do Good. Get Rewarded. Just $0.26/Share!

This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.
Buy
71

AKRO
Akero Therapeutics

Last Price:
32.75
Seasonality Move:
5.92%

7 Day Trial

ALL ACCESS PASS

$ 7

Trade on Tuesday. Profit on Friday. Rinse & Repeat

Get the full details now.

Akero Therapeutics Price Quote

$32.75
+0.02 (+4.97%)
(Updated: November 23, 2024 at 5:24 AM ET)

Akero Therapeutics Key Stats

Buy
71
Akero Therapeutics (AKRO) is a Buy
Day range:
$31.05 - $32.95
52-week range:
$15.32 - $37.00
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
0.00
P/B ratio:
3.09%
Volume:
824.5K
Avg. volume:
636.3K
1-year change:
105.33%
Market cap:
$2.3B
Revenue:
$0
EPS:
$-3.78

How Much Does Akero Therapeutics Make?

Data Unavailable

Is Akero Therapeutics Growing As A Company?

Data Unavailable

Akero Therapeutics Stock Price Performance

What Is Akero Therapeutics 52-Week High & Low?

Akero Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Akero Therapeutics?

Is Akero Therapeutics Cash Flow Positive?

  • What Is AKRO Cash Flow From Operations?
    Cash flow from operations (TTM) is -$211.6M
  • What Is Akero Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $370.4M
  • What Is Akero Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$112.2M

Akero Therapeutics Return On Invested Capital

Data Unavailable

Akero Therapeutics Earnings Date & Stock Price

Akero Therapeutics Competitors

  • Who Are Akero Therapeutics's Competitors?
    Below is a list of companies who compete with Akero Therapeutics or are related in some way:
    • 89bio Inc (ETNB)
    • iBio Inc (IBIO)
    • Madrigal Pharmaceuticals Inc (MDGL)
    • NovaBay Pharmaceuticals Inc (NBY)
    • Palatin Technologies Inc (PTN)

Akero Therapeutics Dividend Yield

Akero Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% -12.36%
Revenue: 0% 0%

Analyst Recommendations

Buy Recommendations: 8
Hold Recommendations: 1
Sell Recommendations: 0
Price Target: 48.27
Upside from Last Price: 47.49%

Major Shareholders

  • How many AKRO shares are owned by institutional investors?
    113.9M AKRO shares are owned by institutional investors
  • How many AKRO shares are owned by insiders?
    1.3M AKRO shares are owned by insiders